William Gillanders News Today

Researchers at Washington University School of Medicine in St. Louis have received an NCI grant that will provide about $10.9 million to research programs for the development of new therapies for pancreatic ductal adenocarcinoma, the deadliest form of pancreatic cancer.

Researchers at Washington University School of Medicine in St. Louis have received a prestigious grant from the National Cancer Institute of the National Institutes of Health (NIH) to support research and clinical trials aimed at improving therapies for pancreatic cancer.

Unlike most people who receive medications yet to be cleared by the FDA, these patients are not getting vaccines as part of a clinical trial.

/PRNewswire/ -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, and the Jaime Leandro Foundation for Therapeutic Cancer Vaccines (JLF),...

The researchers conducted the study in mice with breast cancer and one patient with late-stage pancreatic cancer. The COVID-19 vaccines—designed using bits of genetic information that prime our immune systems to recognize and fight off viral infections—have become lifesavers in the global fight to end the pandemic. Now, the new research has shown that a similar vaccine approach can be used to create personalized vaccines that program the immune system to attack malignant tumors, including ...